Prosight Management, LP Ligand Pharmaceuticals Inc Transaction History

Prosight Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$68.28 - $123.65 $785,220 - $1.42 Million	-11,500 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$63.37 - $107.88 $728,755 - $1.24 Million	11,500 New	11,500 $836,000
Q1 2019 May 15, 2019	SELL	$105.93 - $142.47 $1.33 Million - $1.8 Million	-12,600 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$128.36 - $272.13 $1.62 Million - $3.43 Million	12,600 New	12,600 $1.71 Million

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.01B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.